29 related articles for article (PubMed ID: 19394219)
21. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Vasilevich NI; Parkhill EQ; Glushkov AI; Zilbershtein TM; Mayboroda EI; Boze MA; Cole AG; Henderson I; Zautke NA; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3050-3. PubMed ID: 19394219
[TBL] [Abstract][Full Text] [Related]
22. Role of hepatic desaturases in obesity-related metabolic disorders.
Bjermo H; Risérus U
Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):703-8. PubMed ID: 20823776
[TBL] [Abstract][Full Text] [Related]
23. An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 - 2013).
Powell DA
Expert Opin Ther Pat; 2014 Feb; 24(2):155-75. PubMed ID: 24251719
[TBL] [Abstract][Full Text] [Related]
24. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
25. SB-480848. GlaxoSmithKline.
Rotella DP
Curr Opin Investig Drugs; 2004 Mar; 5(3):348-51. PubMed ID: 15083604
[TBL] [Abstract][Full Text] [Related]
26.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
27.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
